Table of Contents
International Journal of Proteomics
Volume 2015 (2015), Article ID 841769, 12 pages
Research Article

SILAC-Based Quantitative Proteomic Analysis of Diffuse Large B-Cell Lymphoma Patients

1Department of Clinical Chemistry and Transfusion Medicine, Sahlgrenska University Hospital, 413 45 Göteborg, Sweden
2Sahlgrenska Academy, University of Gothenburg, 413 45 Göteborg, Sweden
3Section of Hematology, Kungälv Hospital, 442 83 Kungälv, Sweden
4Section of Hematology and Coagulation, Sahlgrenska University Hospital, 413 45 Göteborg, Sweden
5Department of Pathology and Cytology, Sahlgrenska University Hospital, 413 45 Göteborg, Sweden
6Unit of Hematology, Department of Medicine, Södra Älvsborg Hospital, 504 55 Borås, Sweden

Received 28 December 2014; Accepted 23 March 2015

Academic Editor: Richard Christopherson

Copyright © 2015 Ulla Rüetschi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Diffuse large B-cell lymphoma (DLBCL), the most common lymphoma, is a heterogeneous disease where the outcome for patients with early relapse or refractory disease is very poor, even in the era of immunochemotherapy. In order to describe possible differences in global protein expression and network patterns, we performed a SILAC-based shotgun (LC-MS/MS) quantitative proteomic analysis in fresh-frozen tumor tissue from two groups of DLBCL patients with totally different clinical outcome: (i) early relapsed or refractory and (ii) long-term progression-free patients. We could identify over 3,500 proteins; more than 1,300 were quantified in all patients and 87 were significantly differentially expressed. By functional annotation analysis on the 66 proteins overexpressed in the progression-free patient group, we found an enrichment of proteins involved in the regulation and organization of the actin cytoskeleton. Also, five proteins from actin cytoskeleton regulation, applied in a supervised regression analysis, could discriminate the two patient groups. In conclusion, SILAC-based shotgun quantitative proteomic analysis appears to be a powerful tool to explore the proteome in DLBCL tumor tissue. Also, as progression-free patients had a higher expression of proteins involved in the actin cytoskeleton protein network, such a pattern indicates a functional role in the sustained response to immunochemotherapy.